# Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)

> **NCT06932198** · PHASE1 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 14 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension (PAH)

## Interventions

- **DRUG:** Selexipag Film Coated Tablets
- **DRUG:** Uptravi® Film Coated Tablets

## Key facts

- **NCT ID:** NCT06932198
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-09
- **Primary completion:** 2025-03-03
- **Final completion:** 2025-03-25
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06932198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06932198, "Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06932198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*